Inactive Instrument

Highlights Sunesis Pharmaceuticals, Inc. Nasdaq

Equities

US8673286014

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Reverse Split: 1 of 3.5	21-02-24	FA
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-24	CI
Viracta Therapeutics, Inc. completed the acquisition of Sunesis Pharmaceuticals, Inc. for approximately $100 million in a reverse merger transaction.	21-02-23	CI
SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS	20-12-29	BU
SUNESIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS	20-12-03	BU
Sunesis Pharmaceuticals : to Combine with Viracta Therapeutics in All-Stock Deal	20-11-30	MT
Sunesis Pharmaceuticals, Inc And Viracta Therapeutics, Inc Merger Call	20-11-30	FA
Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement	20-11-30	GL
Viracta Therapeutics, Inc. executed the Offer Letter to acquire Sunesis Pharmaceuticals, Inc. in a reverse merger transaction	20-11-29	CI
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-16	CI
Sunesis Pharmaceuticals : Q3 Beats Street Estimates	20-11-16	MT
Sunesis Pharmaceuticals : Earnings Flash (SNSS) SUNESIS PHARMACEUTICALS Reports Q3 EPS $-0.29	20-11-16	MT
Reverse Split: 1 of 10	20-09-02	FA
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-11	CI
Sunesis Pharmaceuticals, Inc Announces Clinical Update on Vecabrutinib Program	20-06-23	CI
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-10	CI
Sunesis Pharmaceuticals, Inc. Announces Vecabrutinib Phase 1b/2 Clinical Update	20-03-10	CI
Sunesis Pharmaceuticals, Inc. and Millennium Pharmaceuticals, Inc. Announce Amended and Restated License Agreement Dated January 8, 2014 into Two Separate Agreements	19-12-17	CI
Millennium Pharmaceuticals, Inc. Enters into Transaction with DOT Therapeutics-1, Inc	19-12-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sunesis Pharmaceuticals, Inc. Nasdaq

Equities

US8673286014

Highlights

Filters